Solid Organ Transplantation: The Liver
Tacrolimus and Mycophenolate Mofetil in Clinical Liver Transplantation: Experience With a Steroid-Sparing Concept

https://doi.org/10.1016/S0041-1345(98)00296-6Get rights and content

Section snippets

Patients and Methods

In a pilot study 21 patients (age 15 to 66 years) had LTX for end-stage liver disease, including 10 with viral hepatitis B or C infection. Except for an intraoperative bolus of methylprednisolone 500 mg IV given before reperfusion, dual oral immunosuppression consisted of tacrolimus (Prograf, Fujisawa Pharmaceuticals, Osaka, Japan) 2 × 0.05 mg/kg per day, and mycophenolate mofetil (MMF) (Cell Cept, Hoffmann-La-Roche, Grenzach-Whylen, Germany) 30 to 40 mg/kg per day in 11 patients (phase 1).

Results

Fifteen recipients are alive with a functioning graft after a maximum follow-up period of 16 months. Six patients died with functioning grafts between 19 and 22 postoperative days (pod) due to systemic aspergillosis (pod 19, 24), septicemia (pod 51, 122), arterial bleeding due to media necrosis (pod 28), and myocardial infarction (pod 68). Primary nonfunction necessitated five retransplants in four patients. In phase 1, acute rejection occurred in 5 of 11 patients (pod 6 to 72) and was closely

Discussion

This preliminary experience demonstrates that the combination of tacrolimus and MMF is effective after liver transplantation even without any or only short-term steroids. This has also been demonstrated by others.4, 5Whether the obviously better control of immune reactions as well as gastrointestinal side effects in group B is due to the learning phase with closer drug monitoring and rapid dose adjustments or the addition of low does prednisone needs to be seen with more patients.

References (5)

  • R Tur-Kaspa et al.

    J Hepatol

    (1990)
  • B Ringe et al.

    Liver Transplant Surg

    (1997)
There are more references available in the full text version of this article.

Cited by (0)

View full text